Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.

@article{Ma2012TargetingCI,
  title={Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.},
  author={Cynthia X. Ma and Shirong Cai and Shunqiang Li and Christine E. Ryan and Zhanfang Guo and W Timothy Schaiff and Li Lin and Jeremy Hoog and Reece J. Goiffon and Aleix Prat and Rebecca L. Aft and Matthew J. Ellis and Helen Piwnica-Worms},
  journal={The Journal of clinical investigation},
  year={2012},
  volume={122 4},
  pages={1541-52}
}
Patients with triple-negative breast cancer (TNBC) - defined by lack of estrogen receptor and progesterone receptor expression as well as lack of human epidermal growth factor receptor 2 (HER2) amplification - have a poor prognosis. There is a need for targeted therapies to treat this condition. TNBCs frequently harbor mutations in TP53, resulting in loss of the G1 checkpoint and reliance on checkpoint kinase 1 (Chk1) to arrest cells in response to DNA damage. Previous studies have shown that… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 87 extracted citations

p53 as a target for the treatment of cancer.

Cancer treatment reviews • 2014
View 5 Excerpts
Highly Influenced

Cell Death Signaling in Cancer Biology and Treatment

Cell Death in Biology and Diseases • 2013
View 5 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-5 of 5 references

Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF.

Annals of oncology : official journal of the European Society for Medical Oncology • 2005

The ATM - Chk 2 - Cdc 25 A checkpoint pathway guards against radioresistant DNA synthesis

Mailand N Falck J, Bartek J Syljuasen RG, Lukas
-1

Similar Papers

Loading similar papers…